Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Myriad Genetics, Inc.
Type
Public
Traded as NASDAQ: MYGN
Industry Health Care
biopharmaceutical
biotech
Founded Salt Lake City, Utah, United States (1992)
Headquarters Salt Lake City, Utah
Key people
Mark Capone, CEO
Mark Skolnick, Co-Founder
Jerry Lanchbury, CSO
Walter Gilbert, Director, and Vice Chair
Website www.myriad.com

Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy and tailor a patient's drug dose to ensure optimal treatment (personalized medicine), and assess a patient's risk of disease progression and disease recurrence (personalized medicine). The discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: “There is no more exciting story in medical science.” Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics.

Investment goal date:
Dividends reinvested
Myriad Genetics, Inc. MYGN report Q4 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q2 2018
2018-02-05
--
--
Q1 2018
2017-11-07
--
--
Q4 2017
2017-08-08
0.3000
0.1900
Q3 2017
2017-05-02
0.2700
0.0600
Q2 2017
2017-02-07
0.2600
0.0900
Q1 2017
2016-11-01
0.2300
-0.0200
Q4 2016
2016-08-09
0.3600
0.3200
Q3 2016
2016-05-03
0.4100
0.4700
Q2 2016
2016-02-02
0.4500
0.5000
Q1 2016
2015-11-03
0.4100
0.4200
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ACADIAN ASSET MANAGEMENT LLC
1783748
BAILLIE GIFFORD & CO
9922453
BlackRock Fund Advisors
3264023
BlackRock Inc.
9541884
BlackRock Institutional Trust Company, N.A.
1755099
BlueMountain Capital Management, LLC
1000000
Camber Capital Management LLC
4325000
Consonance Capital Management LP
2976356
D. E. Shaw & Co., Inc.
4250049
DIMENSIONAL FUND ADVISORS LP
2642820
DISCIPLINED GROWTH INVESTORS INC /MN
1359197
FIRST TRUST ADVISORS LP
1918172
FRONTIER CAPITAL MANAGEMENT CO LLC
3075954
STATE STREET CORP
3176426
Vanguard Group, Inc
6251030
Major Shareholders
Name Relationship
Total Shares
Holding stocks
MELDRUM PETER D
0.0100% (10424)
ECYT / MYGN /
BEST LAWRENCE C
0.0200% (17500)
HAE / MYGN /
MARSH RICHARD M
0.1800% (137885)
MYGN /
LANCHBURY JERRY S
0.1900% (138809)
MYGN /
HENDERSON JOHN T
0.0600% (42524)
CYTK / MYGN / MYRX /
GILBERT WALTER PHD
0.0200% (12500)
MYGN /
LANGER DENNIS
0.0200% (17500)
DCTH / DRNA / MYGN / MYRX /
Capone Mark Christopher
0.4400% (332175)
MYGN /
Evans James S
0.0600% (48128)
MYGN /
Harrison Robert Gardner
0.0300% (25844)
MYGN /
Phanstiel S. Louise
0.0100% (5000)
MYGN / VSTM /
DREISMANN HEINRICH
0.0200% (17500)
MYGN /
King Gary A.
0.1600% (121917)
MYGN /
Verratti Mark
0.0700% (49200)
CYBX / MYGN /
Hart Jayne B.
0.0400% (26193)
MYGN /
Rogers Ronald S.
0.0200% (16000)
MYGN /
McDade Ralph L
0.1400% (108184)
MYGN /
Riggsbee Richard Bryan
0.1500% (109988)
MYGN /
Tobin Bernard
0.2000% (146172)
MYGN /
Ford Alexander
0.1100% (79800)
MYGN /
% ()